ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 877

Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts

Tomoaki Higuchi1, Yasushi Kawaguchi1, Kae Takagi1, Akiko Tochimoto1, Yuko Ota2, Yasuhiro Katsumata1, Takahisa Gono1, Masanori Hanaoka1, Yuko Okamoto1, Hidenaga Kawasumi1 and Hisashi Yamanaka3, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 210-22 Kawada-Cha Shinjuku-Ku, Tokyo Women's Medical University, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, fibrosis, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose

Systemic sclerosis (SSc) is a connective tissue disease characterized by inflammation, vasculopathy and fibrosis. Tissue fibrosis directly contributes to mortality or quality of life. However, the effective therapy has not been established. Aberrantly activated fibroblasts in the affected area of SSc, which play a main role in the production and remodeling of collagen and other extracellular matrix components, is thought to be a key therapeutic target. Recent researches showed that stimulation of soluble guanylate cyclase (sGC) reverted fibrotic phenotype of SSc and other fibrotic disorders in vivo and in vitro by increasing levels of intracellular cyclic GMP (cGMP). The purpose of the present study is to assess the anti-fibrotic properties of cGMP in cultured fibroblasts from patients with SSc. 

Methods

Skin fibroblasts were obtained from patients with diffuse cutaneous SSc. Intracellular cGMP levels were measured using a commercially available ELISA kit. To increase the intracellular concentration of cGMP, sildenafil, an inhibitor of phosphodiesterase (PDE) 5, was added. Expression of PDE5 and alpha smooth muscle actin (αSMA) were analyzed by immunohistochemistry. Gene expressions related to profibrotic marker were evaluated by quantitative RT-PCR. Western blotting and ELISA were performed to investigate the effects of sildenafil on the downstream pathway of TGF-β. 

Results

PDE5 expression on skin fibroblasts was confirmed by immunohistochemistry. Baseline cGMP levels in SSc skin fibroblasts were significantly higher than those in healthy skin fibroblasts.  Sildenafil increased cGMP levels in a dose dependent manner in skin fibroblasts, and then our results indicated that sildenafil significantly decreased the expression of profibrotic genes, which were augmented by TGF-β1, including COL1A1, COL1A2, CTGF and ACTA2 in SSc skin fibroblasts. Conversely, these inhibitory effects of sildenafil were found to be weak in healthy skin fibroblasts. Also, we confirmed using immunohistochemistry that the protein levels of αSMA in SSc skin fibroblasts were down-regulated by sildenafil. Next, we explored the effects of sildenafil on the signal pathway of TGF-β. Sildenafil significantly reduced phosphorylation of p38 induced by TGF-β1, but did not affect phosphorylation of Smad3. In addition, sildenafil reduced Rho kinase activity.

Conclusion

We demonstrated that sildenafil attenuated the fibrotic phenotype of SSc skin fibroblasts induced by TGF-β1. This effect may be attributed by non-Smad signaling pathways, including MAPK and Rho kinase cascade. Sildenafil has been used for the treatment of SSc -associated pulmonary arterial hypertension and Raynaud phenomenon by its potent vasodilating effect. In addition, our findings would provide the evidence that sildenafil may have the potential to improve fibrotic lesions in SSc.


Disclosure:

T. Higuchi,
None;

Y. Kawaguchi,
None;

K. Takagi,
None;

A. Tochimoto,
None;

Y. Ota,
None;

Y. Katsumata,
None;

T. Gono,
None;

M. Hanaoka,
None;

Y. Okamoto,
None;

H. Kawasumi,
None;

H. Yamanaka,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sildenafil-attenuates-the-fibrotic-phenotype-in-scleroderma-skin-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology